摘要
目的 分析维得利珠单克隆抗体(VDZ)治疗炎症性肠病(IBD)患者的临床疗效。方法 选择2021年2月至2022年5月在空军军医大学第一附属医院接受VDZ治疗的32例IBD患者,分为溃疡性结肠炎(UC)组(n=25)和克罗恩病(CD)组(n=7)。第0、2、6、14、22、30、38、46、54周分别给药1次,随访至第52周。收集临床资料并进行分析。结果 在第6、14、22和52周时,UC组的临床应答率分别为40.0%、68.0%、72.0%和90.0%,临床缓解率分别为8.0%、16.0%、52.0%和80.0%;CD组的临床应答率分别为14.3%、71.4%、85.7%和100%,临床缓解率分别为0、42.9%、57.1%和83.3%。在第22、52周,UC组的内镜应答率分别为72.0%、90.0%,内镜缓解率分别为64.0%、80.0%;CD组的内镜应答率分别为71.4%、83.3%,内镜缓解率分别为42.9%、83.3%。在第6、14、22和52周,UC组的红细胞沉降率(ESR)、超敏C-反应蛋白(hs-CRP)、血小板计数(PLT)均较治疗前显著下降(P均<0.05),血红蛋白(HGB)均较治疗前显著升高(P均<0.05)。在第6、14、22和52周,CD组的ESR均较治疗前显著下降(P均<0.05)。在第6、52周,CD组的hs-CRP均较治疗前显著下降(P均<0.05)。在第6、14和52周,CD组的PLT均较治疗前显著下降(P均<0.05)。在第14、52周,CD组的HGB均较治疗前显著升高(P均<0.05)。随访期间仅1例患者出现过敏性皮疹,VDZ不良反应发生率为3.1%。结论 VDZ能有效诱导及维持IBD疾病缓解,并且其不良反应发生率较低,安全性较高。
Objective This paper intends to analyze the clinical efficacy of vedolizumab(VDZ)in the treatment of patients with inflammatory bowel disease(IBD).Methods Thirty-two IBD patients who received VDZ treatment at the First Affiliated Hospital of Air Force Medical University from February 2021 to May 2022 were selected and divided into the ulcerative colitis(UC)group(n=25)and the Crohn's disease(CD)group(n=7).The patients were administered once in weeks 0,2,6,14,22,30,38,46,and 54,respectively,followed up until week 52,and the clinical data were collected and analyzed.Results At weeks 6,14,22,and 52,the clinical response rates of the UC group are 40.0%,68.0%,72.0%,and 90.0%,respectively,and the clinical remission rates are 8.0%,16.0%,52.0%,and 80.0%,respectively,while the clinical response rates of the CD group are 14.3%,71.4%,85.7%,and 100%,respectively,and the clinical remission rates are 0,42.9%,57.1%,and 83.3%,respectively.At weeks 22 and 52,the endoscopic response rates of the UC group are 72.0%and 90.0%,respectively,and the endoscopic remission rates are 64.0%and 80.0%,respectively,while the endoscopic response rates of the CD group are 71.4%and 83.3%,respectively,and the endoscopic remission rates are 42.9%and 83.3%,respectively.At weeks 6,14,22,and 52,compared with before treatment,the red blood cell sedimentation rate(ESR),hypersensitive C-reactive protein(hs-CRP),and platelet count(PLT)of the UC group are significantly decreased(P<0.05),while the hemoglobin(HGB)is significantly increased(P<0.05).At weeks 6,14,22,and 52,compared with before treatment,the ESR of the CD group is significantly decreased(P<0.05).At weeks 6 and 52,compared with before treatment,the hs-CRP of the CD group are significantly decreased(P<0.05).At weeks 6,14,and 52,compared with before treatment,the PLT of the CD group is significantly decreased(P<0.05).At weeks 14 and 52,compared with before treatment,the HGB of the CD group is significantly increased(P<0.05).During the follow-up period,only one patient developed allergic rash,and the incidence of VDZ adverse reactions is 3.1%.Conclusion VDZ can effectively induce and maintain remission of IBD,with a lower incidence of adverse reactions and higher safety.
作者
王玉龙
方洒
吴开春
时永全
梁洁
韩霜
陈敏
WANG Yulong;WU Kaichun;SHI Yongquan;LIANG Jie;CHEN Min;FANG Sa;HAN Shuang(Department of Gastroenterology,the First Affiliated Hospital of Air Force Medical University,Xi'an 710032,China;Department of Gastroenterology,Xi'an Honghui Hospital,Xi'an 710054,China)
出处
《国际消化病杂志》
CAS
2024年第1期24-28,58,共6页
International Journal of Digestive Diseases
关键词
维得利珠单抗
炎症性肠病
溃疡性结肠炎
克罗恩病
疗效
Vedolizumab
Inflammatory bowel disease
Ulcerative colitis
Crohn's disease
Curative effect
